Meetings - The ASCO Post

This is Part 3 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, D...

/ Expert Perspectives on the Treatment of High-Risk Myelofibrosis

Case 2: Recognizing Cytopenias and Comorbidities in the First-Line Management of Myelofibrosis

This is Part 2 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, ...

hematologic malignancies

/ Expert Perspectives on the Treatment of High-Risk Myelofibrosis

Case 1: Initial Management of a Patient With High-Risk Myelofibrosis

This is Part 1 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, D...

Expert Perspectives on the Treatment of High-Risk Myelofibrosis

Case 3: Managing Myelofibrosis Beyond the First-Line Setting

Case 2: Recognizing Cytopenias and Comorbidities in the First-Line Management of Myelofibrosis

Case 1: Initial Management of a Patient With High-Risk Myelofibrosis

Underlying Mechanisms of Chemoresistance in AML

Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC

Treatment-Resistant Melanoma Novel Checkpoint Inhibitor Combination

Can a Mitochondrial Antioxidant Drive Metastasis

Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer